Junpei Li, Zidong Lu, Xiaole Kong, Yongmin Ma, Xingyuan Zhang, Sukhvinder S Bansal, Vincenzo Abbate, Robert C Hider
Journal: Future medicinal chemistry 2016;7(18):2439-49
PMID: 26670054
BACKGROUND
Deferiprone has proved to be a successful iron selective chelator in a range of pathologies. However, its use is limited by rapid Phase II metabolism, necessitating the administration of large doses. In an attempt to modify metabolic rate of this class of compounds, a range of pegylated 3-hydroxypyridin-4-ones has been synthesized.
EXPERIMENTAL
The synthetic route in which the polyethylene glycol counterparts are introduced to a protected pyran ring involves either a Williamson etherification reaction or direct addition leading to polyethylene glycol-containing precursors.
RESULTS & DISCUSSION
The introduction of the pegylated substituent was found to lead to a relatively low rate of metabolism for some of the derivatives (6a, 6b, 8a and 8b), offering a possible improvement over deferiprone.
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.